Division of Dr. Reddy's Laboratories Ltd.
Latest From OctoPlus NV
This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.
This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.
Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News
GV Prasad, Chairman of the $2.13 billion Indian drug firm Dr. Reddy's Laboratories Ltd. is preparing to take his company from predominantly generics to super generics and untapped innovative niche products. His pet project is lower risk innovation via reverse translation by solving problems with existing molecules.
Darmstadt, Germany-headquartered Merck KGaA has named Boehringer Ingelheim's former head of biopharmaceuticals, Simon Sturge, head of its biosimilars unit – effective 1 March 2014. Mr Sturge will be based at the unit in Canton de Vaud, Switzerland and will report to Stefan Oschmann, a member of Merck's executive board responsible for the company's pharmaceutical businesses. Prior to Boehringer Ingelheim Mr Sturge was CEO of Dutch biotech-company OctoPlus.
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- OctoPlus BV
- Western Europe
- Parent & Subsidiaries
- Dr. Reddy's Laboratories Ltd.
- Senior Management
Susan Swarte, CFO
Kenneth W Bair, SVP, R&D
Gerben Moolhuizen, CBO
- Contact Info
Phone: (31) (0)71 524 40 44
Leiden, 2333 CL
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.